Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic Non-Small Cell Lung Cancer Age: Adult Condition: ALK-positive or ROS1-positive |
Dose: Capsule – 250 mg Frequency: twice daily Note: Select patients based on presence of ALK or ROS1 positivity in tumor specimens. Continue treatment as long as patient is deriving clinical benefit from therapy. |
|
Indication: Systemic Anaplastic Large Cell Lymphoma Age: Adult |
Dose: Capsule – 280 mg/m2 Frequency: twice daily Note: Recommended dosage is based on body surface area. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anaplastic Large Cell Lymphoma Age: children and young adults aged greater than 1 year |
Dose: Capsules – 280 mg/m2 Frequency: twice daily Note: by mouth (oral). Assess the ability to swallow intact capsules before prescribing. Indicated for relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma (ALCL). |
|
Indication: Inflammatory Myofibroblastic Tumors (IMT) Age: adults and pediatric patients aged greater than 1 year Condition: ALK-positive |
Dose: Oral dosage – 280 mg/m2 Frequency: twice daily Note: based on body surface area. Indicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT). |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild-to-moderate (Creatinine Clearance 30-90 mL/min) |
Dose: Not specified Note: No starting dose adjustment is needed; steady-state trough concentrations in these 2 groups were similar to those with normal renal function (ie, Creatinine Clearance greater than 90 mL/min) |
|
Condition: Severe (Creatinine Clearance less than 30 mL/min) or end-stage renal disease |
Dose: Not specified Note: Caution advised |
Administration
- Can be taken with or without food
- Swallow capsules whole
Side Effect
- ALT elevation (76%)
- AST elevation (61%)
- Vision disorder (60%)
- Diarrhea (60%)
- Nausea (55%)
- Lymphopenia (51%)
- Neutropenia (49%)
- Vomiting (47%)
- Constipation (42%)
- Edema (31%)
- Hypophosphatemia (28%)
- Decreased appetite (27%)
- Fatigue (27%)
- Dysgeusia (26%)
- Upper respiratory infection (26%)
- Dizziness (22%)
- Neuropathy (19%)
- Dysesthesia (19%)
- Gait disturbance (19%)
- Hypoesthesia (19%)
- Muscular weakness (19%)
- Neuralgia (19%)
- Peripheral neuropathy (19%)
- Paresthesia (19%)
- Peripheral sensory neuropathy (19%)
- Polyneuropathy (19%)
- Burning sensation in skin (19%)
- Hypokalemia (18%)
- Weight decreased (10%)
- Rash (9%)
- Dyspepsia (8%)
- Pulmonary embolism (6%)
- QT prolongation (5%)
- Bradycardia (5%)
- Pneumonia (4.1%)
- Pneumonitits (4%)
- Renal cyst (4%)
- ARDS (4%)
- Pulmonary embolism (3.5%)
- Syncope (3%)
- Dyspnea (2.3%)
- Hepatic failure (1%)
- Esophagitis (2%)
- Vision loss
- grade 4 (0.2%)
- Hypogonadism
- decreased blood testosterone (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.